Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights the potential of rosemary as a treatment for various types of alopecia, with effects possibly comparable to minoxidil and a favorable safety profile, though further large-scale studies are necessary to confirm these findings.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

In this retrospective case–control study, researchers observed that patients with alopecia areata had a higher prevalence of iron deficiency anemia compared to controls, suggesting a potential comorbidity that may require assessment and management.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

In this review, researchers reported that pyroptosis, a type of inflammatory cell death linked to inflammasome activity, is a key factor in the pathogenesis of alopecia areata and may present new therapeutic opportunities, though most treatments are still in early research stages.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

This review, drawing on scientific literature, explores alopecia areata's pathogenesis and treatment, noting that while therapies like JAK inhibitors show promise, there remains a significant need for more effective and targeted solutions, and a better understanding of the disease mechanisms.

CTP-543 is generally safe for treating alopecia areata.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

In this study, a low-methionine diet significantly improved the health and physical traits of cystathionine β-synthase-deficient mice, contrasting with negative effects on mice with partial deficiency.

This report describes a case of a 75-year-old woman whose diagnosis of hypopituitarism led to significant weight gain and improved physical function with treatment, highlighting the potential for overcoming frailty when investigating underlying causes in elderly patients.

In this study, twice-weekly and thrice-weekly dutasteride improved hair growth and were well-tolerated, although thrice-weekly dosing did not significantly outperform finasteride 1 mg daily for increasing hair count.

This case report suggests that isolated amylase deficiency can lead to failure to thrive in children, and pancreatic enzyme supplementation may improve associated symptoms.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

In an open-label clinical trial, this study found that applying Narasimham Hair Oil thrice weekly for 8 weeks significantly improved hair density, thickness, and scalp health among participants with hair thinning, with benefits persisting after treatment, and 95% reporting user satisfaction without adverse effects.

This case report describes a 15-month-old girl with a history of dermatitis, eosinophilic esophagitis, and failure to thrive, leading to a suspected diagnosis of Netherton syndrome.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

This study found that in female breast cancer patients, supplementation with 400 mg IND02 (Cinnamon bark extract) thrice daily during chemotherapy significantly reduced severe weight loss and hair loss compared to placebo, with the treatment being well-tolerated and safe.

This case report describes a 7-year-old girl whose allergic conjunctivitis went underdiagnosed and undertreated, resulting in poor prognosis due to the challenges associated with her young age and inability to verbally communicate symptoms.

This study reports that the symptoms and immunological findings in two children with diverse autoimmune-like conditions were ultimately attributed to lysinuric protein intolerance, confirmed by genetic analysis in one child.

This study identified 1277 genomic regions selected for traits in indigenous Chinese goats, including cashmere fiber, reproduction, size, and high-altitude adaptation, revealing key candidate genes for these phenotypes through whole-genome resequencing.

This study reported that mice on a phenylalanine-deficient diet showed symptoms such as weight loss, gastric dilation, and thymic depletion, which echo human phenylalanine deficiency manifestations.

This review article discusses various pediatric malabsorption disorders, highlighting their symptoms, causes, diagnostic methods, and treatment but provides no new clinical results.

This case report describes a 17-year-old patient diagnosed with Netherton syndrome, characterized by pruritic dry skin, short brittle hair, and elevated IgE levels, treated with antihistamines and emollients.

This case report describes a 2-month-old infant with a severe seborrhea-like skin eruption and respiratory distress, similar to symptoms that led to a sibling's death from Gram-negative septicemia.

This case report describes a 1-month-old male infant with Netherton syndrome, characterized by severe hypernatremia, skin and scalp issues, highlighting the syndrome's complications, including growth retardation and infection risks in early life.